A complete screening of the CFTR gene by DGGE and DNA sequencing was performed in patients with sarcoidosis. In 8/26 cases, missense and splicing CFTR gene mutations were found, a significant difference over controls (9/89) from the same population (P = 0.014). The odds ratio for a person with a CFTR gene mutation to develop the disease is 3.95 (1.18 < OR < 13.26). Seven different CFTR gene mutations were observed: R75Q, R347P, 621 + 3 A/G, 1898 + 3 A/G, L997F, G1069R, and a novel mutation which was detected in this study, I991V. R75Q mutation was present in 3/26 patients, a significant increase (P = 0.01) in cases over controls, indicating its preferential association with sarcoidosis. A trend towards disease progression was observed in patients with CFTR gene mutations compared to patients without mutations. These data suggest that CFTR gene mutations predispose to the development of sarcoidosis. European Journal of Human Genetics (2000) 8, 717-720.
Introduction
Sarcoidosis is a multisystem granulomatous disorder characterised by non-caseous granulomata and an accumulation of immunocompetent cells at sites of disease activity. 1 The aetiology of the disease is not known, but there is a growing body of evidence strongly suggesting that in sarcoidosis, as in other complex traits, environmental factors may contribute to the onset of the disorder in genetically predisposed individuals. 2 A genetic component in sarcoidosis is indicated by the varying incidence among different ethnic groups, and by the occurrence of familial clustering of cases. 3, 4 Furthermore, genetic factors are believed to play an important role in determining the pattern of the disease, its severity, and prognosis: in other words, genetic variation may underlie the different phenotypes of the disease. 5 No linkage to a chromosomal region where candidate genes for two granulomatous disorders with clinical similarities to sarcoidosis are located has been observed in African-American sib pairs with sarcoidosis. 6 During a CFTR gene mutation screening in pulmonary diseases, we previously analysed a group of patients with a variety of obstructive and non-obstructive pulmonary diseases. 7 In that paper, we reported that 5/8 (62%) of sarcoidosis patients had a mutation in the CFTR gene. This high incidence in a limited number of patients prompted us to analyse a second enlarged series of patients to confirm the data. We now report that in 26 new patients with sarcoidosis there is an increased frequency of mutations in the CFTR gene. These data confirm the initial finding, and indicate that the CFTR gene may increase the genetic susceptibility to the development of the disease. Preliminary findings were communicated at two international meetings.
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Materials and methods
Patients
Twenty-six adult unrelated consecutive patients with sarcoidosis were collected. All patients were Italians of white ancestry, and living in a northern region of Italy (Lombardy). Diagnosis and assessment of sarcoidosis was performed according to the recently published guidelines. 10 Chest radiographic staging was assessed according to De Remee.
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Twenty-three out of 26 patients had sarcoidosis confirmed by one or more biopsies. Two patients refused biopsy. Both were in chest radiologic stage II and they showed clinical features consistent with clinical diagnosis of sarcoidosis. In one patient, presenting with classical Löfgren's syndrome, confirmatory biopsy was not needed. 10 For these reasons, the three patients with clinical diagnosis of sarcoidosis were included in our series (see Table 1 ). The control group was formed by 89 consecutive patients presenting to the same department for other pulmonary diseases (27 with chronic bronchitis, 25 with emphysema, 26 with lung cancer, four with active tuberculosis, five with bacterial pneumonia, two with spontaneous pneumothorax. 7 All subjects were of the same ethnic and geographic origin as the sarcoidosis patients. In the control group, assessment of the underlying disease excluded the coexistence of sarcoidosis.
Mutation analysis
Genomic DNA was extracted from peripheral whole blood samples by standard methods. 12 A complete analysis of all the 27 exons of the CFTR gene and their intronic flanking regions was performed by denaturing gradient gel electrophoresis (DGGE), as previously reported. 7 By this method, individual genotypes were correctly determined for 73/74 CFTR gene mutations not originally detected by DGGE, and located at different sites all along the gene, with a sensitivity of 98.6%.
Mutations detected by DGGE analysis were identified by automatic DNA sequencing with the ABI Prism 377 sequence analyser (PE Applied Biosystems, Foster City, CA, USA). Moreover, individuals were genotyped for three intronic mutations: IVS8-6 T n N, 13 IVS8 (TG) m -T n , 14 3849 + 10Kb C → T. 15 Analysis of the effect of mutations on splicing efficiency was performed with the use of the software BCM Gene Finder/HSPL, available on the Baylor College of Medicine Search Launcher website (http://dot.imgen.bcm.tmc. edu:9331).
Statistical analysis
The frequency of mutations was determined by patient counts. Differences between patients and controls were compared by Fisher's exact test, using the EPI Info software (version 5.01). A P value of less than 0.05 was considered to indicate statistical significance. From the previous finding of 5/8 sarcoidosis patients with CFTR gene mutations compared with 9/89 individuals with other pulmonary diseases from the same population, 7 it was calculated that a new sample of 28 patients would have the power of 80% to detect a CFTR gene effect with an odds ratio of 5.
Results
We performed the complete DGGE analysis of the CFTR gene in the 26 patients with sarcoidosis. We found eight patients with mutations (30.8%) in the CFTR gene, as reported in Table 2 , column 2. This frequency represents a significant I991V is a novel mutation here described for the first time: it changes isoleucine to valine (both hydrophobic residues) in the second transmembrane domain. Isoleucine is a conserved residue in 4/5 species, and valine is present in the fifth species. 20 The frequency of three common mutations which modify gene expression by alternative splicing (IVS8 TG m -T n ), or by the efficiency of protein maturation (M470V) was not different from controls (see Table 2 , columns 4 and 5, respectively). In particular the IVS8-5T allele, which determines the production of increased amounts of transcripts lacking exon 9, 21 was found in 2/26 patients, not statistically different from controls (12/89). Several common polymorphisms not thought to cause CF, and including same sense mutations (1716 G/A, 2694 T/G,  3417 A/T, 4002 A/G, 4404 C/T, and 4521 G/A) , and deep intronic mutations (186-13 C/G, 875 + 40 G/A, IVS6 (GATT) n , and 3041-71 G/C) were found. No significant difference was detected between cases and controls for any of these common polymorphisms.
Discussion
These data indicate a significant excess of CFTR gene mutations in sarcoidosis patients. The data confirm, in a second series of patients from the same department, the excess of CFTR gene mutations found in our first report, in which 5/8 patients with sarcoidosis were found to carry CFTR gene mutations. 7 The total of this study plus the previous one When the 34 sarcoidosis patients are subdivided into those with (CFTR + ) and those without (CFTR-) CFTR gene mutations, and several clinical parameters are analysed, no significant differences were observed for mean age and symptoms at onset of the disorder, duration of the disease, outcome, and development of airflow obstruction. Interesting, but not significant, differences were the increase in CFTR + patients compared with CFTR-patients of: 1) chest radiologic stage I at entry (39% vs 24%);
2) relapses (58% vs 44%);
3) extrapulmonary localisations (31% vs 19%); and 4) chest radiologic stage progression (30% vs 11%), respectively.
This is an indication of a possible increased severity of the disease in the presence of CFTR gene mutations.
The mechanism of CFTR gene involvement in sarcoidosis aetiopathogenesis is unknown. Sarcoidosis is a complex disease in which genetic and environmental factors may play The phase of the mutations is not known, as no segregation analysis was possible.
CFTR gene mutations in sarcoidosis C Bombieri et al y a role. Based on the fact that the granulomatous inflammation in sarcoidosis may be determined by a bacterium or a virus, and that the CFTR gene acts as a receptor for Pseudomonas aeruginosa 22 and Salmonella typhi, 23 an hypothesis is that the presence of CFTR gene mutations modify the effect of infection on disease onset and development. Further studies are needed to investigate the possible role of CFTR in determining a genetic predisposition to the disease.
